QGEN vs MEDP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
QGEN · Qiagen NV$50.33 ▼ 1.04%
MEDP · Medpace$653.11 ▲ 2.86%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- QGEN +17.6%
- MEDP +8.8%
Head to head
| Metric | QGEN | MEDP |
|---|---|---|
| Price | $50.33 | $653.11 |
| Change today | ▼ 1.04% | ▲ 2.86% |
| Market cap | $10.39B | $18.27B |
| Return, 3 months | +14.8% | +8.4% |
| Return, year to date | +12.9% | +16.3% |
| Return, 1 year | +16.6% | +10.9% |
| P/E (TTM) | 27.7 | 36.3 |
| P/B | 3.0 | 31.2 |
| P/E percentile vs own 5y | 43rd | 75th |
| Dividend yield | 0.70% | – |
| Revenue growth (YoY, latest qtr) | +0.3% | +8.5% |
| Net profit growth (YoY) | +7.4% | +23.7% |
| Gross margin | 62.2% | 29.1% |
| Operating margin | 24.6% | 21.4% |
| Net margin | 19.5% | 18.2% |
| Return on equity | 11.9% | 117.9% |
| Analyst target vs. price | +1.7% | +5.8% |
| Analyst buy share | 45% | 38% |
| RSI (14) | 68 | 53 |
| 30-day volatility | 30.1% | 36.6% |
| Max drawdown, 1 year | -41.4% | -36.6% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MEDP is the largest of the group by market value.
- QGEN has returned the most over the past year.
- QGEN carries the lowest trailing P/E.
- MEDP is growing revenue fastest.
- QGEN keeps the most profit per dollar of sales.
- QGEN has been the calmest stock over the last 30 days.